6 completed, 5 terminated, 1 active not recruiting, 1 recruiting. 7 Phase 2, 6 Phase 1, 3 Phase 3.
By phase and status
Follow andecaliximab: new trials by email Literature Review of andecaliximab trials Research Report on andecaliximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
Andecaliximab - Heterotopic Ossification (HO) | Phase 1 / Phase 2 | Recruiting | Ashibio Inc | 10 | 2025-05-14 | 2025-06-17 |
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Andecaliximab, Placebo - Fibrodysplasia Ossificans Progressiva | Phase 2 / Phase 3 | Active not recruiting | Ashibio Inc | 92 | 2024-10-25 | 2025-10-14 |
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Andecaliximab, Placebo, Methotrexate - Rheumatoid Arthritis | Phase 2 | Terminated | Gilead Sciences | 15 | 2016-12-15 | 2018-06-27 |
Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis
Andecaliximab, Placebo - Cystic Fibrosis | Phase 2 | Terminated | Gilead Sciences | 6 | 2016-11-04 | 2018-08-17 |
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Andecaliximab, S-1, Cisplatin - Gastric Adenocarcinoma | Phase 1 | Terminated | Gilead Sciences | 36 | 2016-09-20 | 2020-12-24 |
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Andecaliximab, Nivolumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Completed | Gilead Sciences | 144 | 2016-09-01 | 2020-09-18 |
Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Andecaliximab, Placebo, Leucovorin - Gastric Adenocarcinoma | Phase 3 | Completed | Gilead Sciences | 432 | 2015-10-13 | 2020-05-26 |
Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis
Andecaliximab, Placebo - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 165 | 2015-09-01 | 2019-04-10 |
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
Andecaliximab, Placebo - Crohn's Disease | Phase 2 | Terminated | Gilead Sciences | 187 | 2015-04-30 | 2019-04-23 |
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis
GS-5745, Placebo to match GS-5745 - Rheumatoid Arthritis | Phase 1 | Completed | Gilead Sciences | 18 | 2014-08-01 | 2015-06-29 |
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
Andecaliximab, Placebo to match Andecaliximab - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Gilead Sciences | 11 | 2014-03-11 | 2020-09-09 |
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Andecaliximab, Gemcitabine, Nab-paclitaxel - Pancreatic Cancer, Non-small Cell Lung Cancer | Phase 1 | Completed | Gilead Sciences | 236 | 2013-03-29 | 2020-06-02 |
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis
Andecaliximab, Placebo to match Andecaliximab - Ulcerative Colitis | Phase 1 | Completed | Gilead Sciences | 74 | 2013-03-28 | 2021-02-01 |
Conditions studied
Arthritis, Rheumatoid (2) · Colitis, Ulcerative (2) · Ossification, Heterotopic (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Crohn Disease (1) · Cystic Fibrosis (1) · Hallux Valgus (1) · Inflammation (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Myositis (1) · Myositis Ossificans (1) · Pancreatic Neoplasms (1)
Sponsors
Gilead Sciences (11) · Ashibio Inc (2)
Countries
United States (10) · Hungary (6) · Australia (5) · France (5) · United Kingdom (5) · Belgium (4) · Czechia (4) · Italy (4) · Poland (4) · Spain (4) · Canada (3) · Germany (3) · Romania (3) · Netherlands (2) · New Zealand (2)
Top investigators
Andrew Park, MD (1) · David Gossage, MD (1)
Results publications
PMID 25961845, PMID 29287749, PMID 29691300, PMID 29846530, PMID 34893523, PMID 34992093, PMID 35773363
NIH funding
2015 (3), 2016 (2), 2014 (1)